Xcout IntelCARGO Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to CARGO Therapeutics, Inc. among biotechnology companies — ranked by similarity to what CARGO Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see CARGO Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About CARGO Therapeutics, Inc.
CARGO Therapeutics, Inc. is a U.S. clinical-stage biotechnology company developing next-generation CAR T-cell therapies for cancer. Its lead program, firicabtagene autoleucel (CRG-022), has been investigated for relapsed or refractory large B-cell lymphoma, serving patients with serious hematologic malignancies.
CARGO Therapeutics, Inc. at a glance
CARGO Therapeutics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $68.8M in February 2023.
CARGO Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $68.8M | — | |
| Series A | $200M | 14 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 CARGO Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to CARGO Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
Biotech
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Similar biotechnology company
Carisma Therapeutics is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, focused on discovering and developing engineered macrophage-based immunotherapies.
Biotech
Kite Pharma is a biopharmaceutical company that develops and manufactures custom CAR T-cell therapies to treat certain types of blood cancer. The company utilizes patients' own engineered immune cells to target and attack cancer, serving patients diagnosed with conditions such as lymphomas.
Similar biotechnology company
KiraGen Bio is a Boston-based biotechnology company pioneering the development of AI-driven, multiplex gene-edited CAR-T cell therapies designed to target and block tumor suppression.
Similar biotechnology company
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Similar biotechnology company
BrainChild Bio is a clinical-stage biotechnology company that develops CAR-T cell therapies to treat tumors in the central nervous system (CNS). The company prioritizes pediatric patients with brain tumors while also extending its technology platform to address adult indications such as glioblastoma and brain metastases.
Similar biotechnology company
CARMA Therapeutics Inc., now known as Carisma Therapeutics, is a biotechnology company founded in 2016 and headquartered in Philadelphia, Pennsylvania, focused on addressing oncology gene therapies.
Similar biotechnology company
CaroGen Corporation develops RNA-based artificial virus platforms and immunotherapies to treat infectious diseases and cancer. The company's pipeline includes late-stage preclinical candidates such as CARG-2020 for ovarian cancer and CARG-201 for chronic hepatitis B.
Similar biotechnology company
Recourse Biologics is a biotechnology company that develops first-in-class immunotherapeutics for oncology. Its lead molecule, RB101, is designed to enhance tumor-killing cell persistence, memory formation, and cytotoxicity while avoiding systemic toxicity.
Similar biotechnology company
KAHR Bio is a biotechnology company developing immunotherapies, particularly engineered fusion-protein therapies intended to activate or modulate immune responses against cancer. Its work is aimed at oncology patients and potential biopharmaceutical partners.
Biotech
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of CARGO Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for CARGO Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →